Jade Biosciences, Inc. SEC filings JBIO
Jade Biosciences, Inc. has 509 filings in SEC EDGAR's recent list, going back to Jan 8, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Jun 4, 2026 | — |
| 424B5 | Prospectus supplement | Jun 3, 2026 | — |
| 424B3 | Prospectus | May 15, 2026 | — |
| S-8 | Employee stock plan registration | May 7, 2026 | — |
| S-3 | Shelf registration | May 7, 2026 | — |
| S-3 | Shelf registration | May 7, 2026 | — |
| 424B3 | Prospectus | May 7, 2026 | — |
| 424B3 | Prospectus | May 7, 2026 | — |
| S-8 | Employee stock plan registration | Mar 6, 2026 | — |
| 424B3 | Prospectus | Mar 6, 2026 | — |
| 424B3 | Prospectus | Mar 6, 2026 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| S-1 | Registration statement | Dec 22, 2025 | — |
| 424B3 | Prospectus | Dec 19, 2025 | — |
| S-1 | Registration statement | Nov 14, 2025 | — |
| S-8 | Employee stock plan registration | Jun 30, 2025 | — |
| 424B3 | Prospectus | Mar 25, 2025 | — |
| S-4/A | Filing | Mar 24, 2025 | — |
| S-4/A | Filing | Mar 14, 2025 | — |
| S-4/A | Form s-4/a | Feb 24, 2025 | — |
| S-4/A | Form s-4/a | Jan 22, 2025 | — |
| S-4 | Registration for a merger or exchange | Dec 3, 2024 | — |
| S-3 | Shelf registration | Jun 10, 2024 | — |
| S-8 | Employee stock plan registration | Jan 8, 2024 | — |
| 424B5 | Prospectus supplement | Apr 5, 2023 | — |
| S-8 | Employee stock plan registration | Mar 29, 2023 | — |
| S-3 | Shelf registration | Aug 15, 2022 | — |
| S-8 | Employee stock plan registration | Mar 30, 2022 | — |
| S-8 | Employee stock plan registration | Jun 30, 2021 | — |
| 424B4 | Prospectus | Jun 30, 2021 | — |
| S-1MEF | Filing | Jun 29, 2021 | — |
| S-1/A | Amended registration statement | Jun 25, 2021 | — |
| S-1/A | Amended registration statement | Jun 24, 2021 | — |
| S-1/A | Amended registration statement | Jun 17, 2021 | — |
| S-1 | Registration statement | Jun 9, 2021 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1798749
- Former names
- Aerovate Therapeutics, Inc. (until Apr 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.